Atrovent

Atrovent is the brand name for ipratropium bromide, a short-acting anticholinergic (muscarinic antagonist) bronchodilator used to relieve bronchoconstriction in chronic obstructive pulmonary disease (COPD) and, in some cases, asthma. Available as a metered-dose inhaler (MDI) and as a nebuliser solution, Atrovent works by blocking muscarinic receptors in the airways, preventing bronchoconstriction and reducing mucus secretion. It is used as a short-acting bronchodilator to provide symptomatic relief of breathlessness and wheeze.

Role in COPD and Asthma Management

In COPD, Atrovent is used as maintenance therapy to relieve persistent bronchospasm and breathlessness. While it has largely been superseded for regular use by longer-acting anticholinergic bronchodilators (LAMAs) such as tiotropium, Atrovent remains an important option in COPD management, particularly when rapid bronchodilation is needed alongside a short-acting beta-2 agonist. In acute asthma, ipratropium bromide is used in combination with salbutamol via nebuliser in hospital or emergency settings to provide additional bronchodilation. It is not generally used as a first-line bronchodilator in chronic asthma management.

How Atrovent Differs from Beta-2 Agonists

Unlike salbutamol and other beta-2 agonists, which work by stimulating beta-2 receptors to directly relax airway smooth muscle, Atrovent works indirectly by blocking the parasympathetic (cholinergic) bronchoconstriction mediated by acetylcholine through muscarinic receptors. Its onset of action is slightly slower than salbutamol (approximately 15 minutes versus 5 minutes), and its duration of action is longer (approximately 4-6 hours). Atrovent also reduces airway secretions, which can be beneficial in COPD. Because it works through a different mechanism, it can be used synergistically with beta-2 agonists for greater bronchodilation.

How to Use the Atrovent Inhaler

Shake the Atrovent metered-dose inhaler before each use. Remove the cap, breathe out gently, then place the mouthpiece in your mouth and breathe in slowly and steadily while pressing the canister to release one puff. Hold your breath for 10 seconds, then breathe out slowly. If a second puff is prescribed, wait at least 30 seconds between puffs.

The standard dose for COPD is 1 to 2 puffs (20 to 40 mcg) three to four times daily. Clean the plastic casing with warm water regularly and allow it to dry completely before reassembly. If your need for Atrovent is increasing significantly, contact your GP or respiratory team, as this may indicate a worsening of your lung condition.

The standard adult dose of Atrovent (ipratropium bromide) via MDI is 20-40 mcg (1-2 puffs of 20 mcg per actuation) inhaled three to four times daily. The maximum recommended dose via MDI is 40 mcg four times daily (160 mcg total daily dose).

For nebulisation in adults (used primarily in acute settings), the dose is 0.25-0.5 mg (250-500 mcg) three to four times daily via nebuliser, diluted with normal saline if required.

In elderly patients, standard doses are used. Elderly individuals may be more sensitive to anticholinergic side effects such as urinary retention, dry mouth, and constipation, and should be monitored accordingly.

No dose adjustment is routinely required for renal or hepatic impairment given the minimal systemic absorption of inhaled ipratropium. However, caution is advised in patients with pre-existing urinary retention or narrow-angle glaucoma, regardless of organ function.

Atrovent can be used in children aged 6 years and above for COPD and asthma under specialist supervision, with doses adjusted by weight and age. Paediatric use should be guided by a respiratory paediatrician.

Atrovent is generally well tolerated at recommended inhaled doses, with the most common side effects being localised anticholinergic effects in the mouth and throat.

Common Side Effects

The following side effects occur in a meaningful proportion of patients and are largely related to the anticholinergic properties of ipratropium:

• Dry mouth (most commonly reported side effect)
• Throat irritation or cough after inhalation
• Headache
• Nausea
• Constipation
• Urinary hesitancy (particularly in men with benign prostatic hyperplasia)
• Blurred vision if the aerosol accidentally enters the eyes

Serious Side Effects

The following serious adverse effects require prompt medical attention:

• Acute narrow-angle glaucoma: if the inhaler aerosol contacts the eyes directly, it can precipitate acute angle-closure glaucoma presenting with eye pain, redness, blurred vision, and seeing coloured halos; this is a medical emergency
• Urinary retention: inability to pass urine, particularly in men with prostatic enlargement; requires urgent catheterisation if it occurs
• Paradoxical bronchospasm: sudden worsening of breathlessness immediately after inhalation; this rare reaction requires immediate use of a fast-acting bronchodilator and medical assessment
• Severe allergic reactions: anaphylaxis, angioedema, urticaria, or rash
• Supraventricular tachycardia or atrial fibrillation (rare, more common with high-dose nebulised ipratropium)

Eye Contact and Glaucoma Risk

Take care to avoid the Atrovent aerosol from entering the eyes. Direct eye contact with ipratropium bromide can precipitate acute narrow-angle glaucoma, a painful and sight-threatening condition requiring emergency ophthalmological treatment. This risk is particularly relevant when using a nebuliser mask rather than a mouthpiece. Patients with pre-existing narrow-angle glaucoma must use Atrovent with particular caution and be informed of this risk. If eye symptoms such as sudden pain, blurred vision, or coloured halos develop after use, seek immediate medical attention. Patients with a diagnosis or family history of glaucoma should inform their ophthalmologist before starting ipratropium treatment.

Urinary Retention, Pregnancy, and Drug Interactions

Atrovent should be used with caution in men with benign prostatic hyperplasia or other causes of urinary outflow obstruction, as its anticholinergic properties can precipitate urinary retention. Patients should be counselled to seek prompt medical attention if they are unable to pass urine. Use of Atrovent alongside other anticholinergic medicines (such as tricyclic antidepressants, antihistamines, and bladder antimuscarinic drugs) can result in additive anticholinergic effects. During pregnancy, ipratropium should only be used when the benefit clearly outweighs any theoretical risk; it is generally considered to be of low systemic risk given its minimal absorption, but specialist advice should be sought. It is not known whether ipratropium is excreted in breast milk in clinically significant quantities.

Atrovent is contraindicated in the following circumstances:

• Known hypersensitivity to ipratropium bromide, atropine, or related anticholinergic compounds, or any excipient in the formulation (including soya lecithin or peanut protein in some formulations; soya/peanut allergy should be checked)
• History of hypersensitivity to atropine or its derivatives
• Known narrow-angle glaucoma (use with extreme caution; not absolute if ophthalmological monitoring is in place)
• Urinary retention due to bladder neck obstruction or significant benign prostatic hyperplasia (relative contraindication)
• Children under 6 years of age without specialist paediatric guidance
• Use with other inhaled anticholinergic bronchodilators concurrently (duplicates the mechanism without benefit)
• Patients with known hypersensitivity to soya lecithin or related food products (peanuts or soya) when using formulations containing these excipients